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Letters to the EditorReply to: Hepatocyte iron accumulation: A new string to
ribavirin’s antiviral bow?This is a reply to the letter to the Editor by Ryan and Crowe:
We thank Drs. J.D. Ryan and J. Crowe for their comments to our
recent article [1]. In their letter, they discuss earlier reports
showing that prolonged treatment of HCV-infected patients with
ribavirin associates with hepatic iron deposition, mainly in hepa-
tocytes [2,3]. This is largely attributed to extravascular hemolysis,
a known side effect of ribavirin ([2] and references therein) even
though one would expect a predominant distribution of excess
iron within Kupffer cells. The authors further hypothesise that
accumulation of iron within hepatocytes may potentiate the anti-
viral efﬁcacy of this therapeutic regimen, considering that iron
inhibits the replication of HCV in permissive Huh7.5.1 cells [1].
We completely agree that this hypothesis merits further
exploration. It will be interesting to examine the effects of ribavi-
rin in the infectious HCV replicon model, with or without exoge-
nous iron administration. Nevertheless, given the complexity of
the pharmacological responses to ribavirin in vivo, which
impinges on systemic iron trafﬁc, we should be cautious in
extrapolating data from this cell culture model. Moreover, the
iron deposition in hepatocytes of patients did not appear to affect
the ‘‘biochemical or histologic response to ribavirin therapy’’ over
a period of 9 months, even though sustained virological response
(SVR) was not assessed [2]. A more recent prospective study eval-
uated how iron perturbations affect combination therapy with
pegylated interferon and ribavirin [4]. The data revealed a nega-
tive correlation between iron load in Kupffer cells and the pros-
pect of achieving SVR, and did not provide any evidence for
potential beneﬁts of hepatocyte iron accumulation. Further clin-
ical studies with HCV-infected patients and, possibly, also exper-
iments with humanized mouse models for HCV infection [5], may
provide a more clear view on how hepatocyte iron accumulation
interferes with antiviral therapy.of interest
ors who have taken part in this study declared that they
ave anything to disclose regarding funding or conﬂict of
with respect to this manuscript.
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